Literature DB >> 10854857

Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo.

N Sidenius1, C F Sier, F Blasi.   

Abstract

Applying a novel, highly specific and sensitive immunoabsorption/Western blotting technique we have identified in vitro in conditioned cell culture medium and in vivo in human urine different soluble forms of the urokinase-type plasminogen activator receptor (uPAR/CD87). These include the uPAR fragment D2D3 and the never before identified domain 1 (D1) fragment. These forms correspond to fragments previously characterised as biologically active as inducers of chemotaxis and cell adhesion. We find that stimulation of U937 cells is associated with increased uPAR expression, cleavage of surface uPAR, and release of soluble fragments to the culture medium suggesting that monocytes are a source of the circulating and urinary soluble uPAR fragments found in vivo. Our study demonstrates that potentially biologically active uPAR fragments are produced in the human body, indicating a possible function in the regulation of not only proteolysis but also signal transduction related processes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854857     DOI: 10.1016/s0014-5793(00)01624-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  38 in total

1.  Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.

Authors:  Andrew S Gilder; Karra A Jones; Jingjing Hu; Lei Wang; Clark C Chen; Bob S Carter; Steven L Gonias
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

Review 2.  Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor.

Authors:  Hernán Trimarchi
Journal:  World J Nephrol       Date:  2013-11-06

3.  The production of soluble C-type lectin-like receptor 2 is a regulated process.

Authors:  Min Fei; Lei Zhou; Jianhui Xie; Yuanyuan Ruan; Jiejie Xu; Songbin He; Hongjie Shen; Yumin Hu; Shifang Ren; Changgeng Ruan
Journal:  Glycoconj J       Date:  2012-06-27       Impact factor: 2.916

4.  Maspin, the molecular bridge between the plasminogen activator system and beta1 integrin that facilitates cell adhesion.

Authors:  Michael P Endsley; Yanqiu Hu; Yong Deng; Xiaolin He; Debra J Warejcka; Sally S Twining; Steven L Gonias; Ming Zhang
Journal:  J Biol Chem       Date:  2011-05-23       Impact factor: 5.157

Review 5.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

6.  Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.

Authors:  T K Outinen; S Mäkelä; R Huttunen; N Mäenpää; D Libraty; A Vaheri; J Mustonen; J Aittoniemi
Journal:  J Intern Med       Date:  2014-05-14       Impact factor: 8.989

7.  Enhancement of Cutaneous Wound Healing by Dsg2 Augmentation of uPAR Secretion.

Authors:  Felicia Cooper; Andrew M Overmiller; Anthony Loder; Donna M Brennan-Crispi; Kathleen P McGuinn; Molly R Marous; Theresa A Freeman; Natalia A Riobo-Del Galdo; Linda D Siracusa; James K Wahl; Mỹ G Mahoney
Journal:  J Invest Dermatol       Date:  2018-05-09       Impact factor: 8.551

8.  The urokinase receptor can be induced by Borrelia burgdorferi through receptors of the innate immune system.

Authors:  James L Coleman; Jorge L Benach
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

9.  Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis.

Authors:  Boris K Pliyev; Mikhail Yu Menshikov
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

10.  Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.

Authors:  Orla Cunningham; Suzanne Campion; V Hugh Perry; Carol Murray; Nicolai Sidenius; Fabian Docagne; Colm Cunningham
Journal:  Glia       Date:  2009-12       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.